|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Discovery of tissue selective liver X receptor agonists for the treatment of atherosclerosis without causing hepatic lipogenesis.
|
31499362 |
2019 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Phosphorylation of hepatic farnesoid X receptor by FGF19 signaling-activated Src maintains cholesterol levels and protects from atherosclerosis.
|
30996006 |
2019 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The top Ingenuity Pathway Analysis canonical pathways were Farsenoid X Receptor and Retinoid Receptor (FXR/RXR; (P = 1.86 × 10<sup>-7</sup>), Liver X Receptor and Retinoid Receptor (LXR/RXR; P = 2.88 × 10<sup>-6</sup>), and atherosclerosis signalling (P = 3.80 × 10<sup>-6</sup>).
|
30026549 |
2018 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Functional interplay between liver X receptor and AMP-activated protein kinase α inhibits atherosclerosis in apolipoprotein E-deficient mice - a new anti-atherogenic strategy.
|
29394501 |
2018 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Krüppel-Like Factor 4 Regulation of Cholesterol-25-Hydroxylase and Liver X Receptor Mitigates Atherosclerosis Susceptibility.
|
28794002 |
2017 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A novel small molecule liver X receptor transcriptional regulator, nagilactone B, suppresses atherosclerosis in apoE-deficient mice.
|
27460841 |
2016 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD40 silencing with a specific siRNA ameliorates progression of experimental atherosclerosis in ApoE<sup>-/-</sup> mice, and evidences a role for NF-κB, Taf3, Xpr1, and miR-125b in the pathogenesis of atherosclerosis.
|
27835742 |
2016 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, activation of cholesterol efflux pathways by HDL infusions or liver X receptor activation results in suppression of hematopoietic stem and multipotential progenitor cell mobilization and extramedullary hematopoiesis, leading to decreased production of monocytes and neutrophils and suppression of atherosclerosis.
|
24385509 |
2014 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
SIRT1 prevents atherosclerosis via liver‑X‑receptor and NF‑κB signaling in a U937 cell model.
|
23652462 |
2013 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice.
|
22918042 |
2012 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Liver X receptor agonist methyl-3β-hydroxy-5α,6α-epoxycholanate attenuates atherosclerosis in apolipoprotein E knockout mice without increasing plasma triglyceride.
|
21071998 |
2010 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Liver X receptor modulators: effects on lipid metabolism and potential use in the treatment of atherosclerosis.
|
19101522 |
2009 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several drugs and nonpharmacologic compounds are ligands for the liver X receptor, pregnane X receptor and other receptors, activate P450 and other genes involved in cholesterol elimination, prevent or regress atherosclerosis and reduce cardiovascular events.
|
18633604 |
2008 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Discovery of phenyl acetic acid substituted quinolines as novel liver X receptor agonists for the treatment of atherosclerosis.
|
17034119 |
2006 |